A new systematic review reveals promising results for oncolytic viral therapy in treating nonmelanoma skin cancers and ...

Patients with chronic lymphocytic leukemia (CLL) who experience Richter transformation have a poor prognosis, but ibrutinib ...

Imagine a super-charged immune cell that can launch a focused attack on stubborn solid tumors -- a smart fighter that destroys cancer cells for days without tiring. Biomedical engineers have made this ...

Large granular lymphocytic leukemias (LGLLs) are a heterogeneous group of rare chronic lymphoproliferative disorders characterized by the clonal ...

Calibr-Skaggs Institute for Innovative Medicines, the drug discovery division of Scripps Research, announced today that the FDA has cleared their investigational new drug (IND) application to study ...

Soligenix is enrolling patients in its FLASH2 study, with a formal interim analysis anticipated early in 2026. <li /> SNGX's HyBryte is a ...

These names in the biotech sector are seeing a substantial increase in search activity today, as determined by InvestingChannel. They include: ...

Pembrolizumab shows clinical promise as a treatment for mycosis fungoides and Sézary syndrome, achieving a response in nearly ...

Citius Oncology, Inc.’s CTOR share price has dipped by 10.12%, which has investors questioning if this is right time to buy.

Compared to the IV infusion of the blockbuster cancer drug Keytruda, subcutaneous Keytruda can cut the time spent in ...

FDA Breakthrough Therapy Designation granted to lacutamab for relapsed or refractory Sézary syndrome New data, including lacutamab improved health-related quality of life data from TELLOMAK ...